Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ADADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA)

NASDAQ Global Market · Currency in USD
$10.68 ▼ -0.27 (-2.47%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.69 ▲ +0.01 (+0.09%)
Pre-market: Oct 26, 4:00 AM ET

Summary

Previous Close
$10.95
Open
$10.88
Day's Range
$10.56 – $10.95
52 Week Range
$7.21 – $20.46
Volume
1,740,919
Avg. Volume
2,841,820
Market Cap
$2.39B
Beta (5Y Monthly)
0.77
PE Ratio (TTM)
14.83
EPS (TTM)
$0.74
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$18.67

Profile: ADMA Biologics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
644
CEO
Adam S. Grossman

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI).

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $0.20 · Revenue est. $138.11M
DateEst.Actual
Aug 5, 2026$0.16$0.16Miss
May 6, 2026$0.19$0.19Miss
Feb 25, 2026$0.19$0.20Beat
Nov 5, 2025$0.16$0.16Beat
Aug 6, 2025$0.14$0.15Beat
May 7, 2025$0.16$0.14Miss

Analyst view

Consensus price target
$18.67 ▲ +74.8%
Range $17.00 – $21.00
Rating: Buy
Buy 90% · Hold 10% · Sell 0%

Similar stocks

Get free alerts on ADMA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.